Physician profile
Edda Casanova
NPI 1215922695
$2,384.56
in general payments reported to CMS, 2019-2025
18 companies · $330 in 2025
The $330 reported for 2025 was more than what a typical Child & Adolescent Psychiatry provider received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $693 · 2020: $497 · 2021: $211 · 2022: $175 · 2023: $203 · 2024: $276 · 2025: $330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $810.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $810.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $436.02 | 2019-2025 | Abilify Asimtufii, Rexulti |
| Supernus Pharmaceuticals, INC. | $346.59 | 2021-2025 | Qelbree |
| Ironshore Pharmaceuticals INC. | $269.47 | 2019-2023 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $198.86 | 2019-2022 | |
| Tris Pharma INC | $179.46 | 2019-2025 | Onyda Xr, Dyanavel Xr |
| Sunovion Pharmaceuticals INC. | $175.92 | 2019-2021 | |
| Lundbeck LLC | $135.32 | 2019-2023 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $128.40 | 2019-2025 | Austedo Xr, Austedo Xr |
| Shire North American Group INC | $122.86 | 2019 | |
| Janssen Pharmaceuticals, INC | $101.14 | 2020-2025 | Invega Sustenna, Spravato |
| Corium, LLC | $68.94 | 2022-2023 | Azstarys |
| Vanda Pharmaceuticals INC. | $45.10 | 2019 | |
| Noven Therapeutics, LLC | $39.45 | 2020 | |
| Collegium Pharmaceutical, INC. | $35.98 | 2025 | Jornay Pm |
| Vertical Pharmaceuticals, LLC | $34.94 | 2024 | Relexxii |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $33.76 | 2020-2025 | Caplyta |
| Alkermes, INC. | $17.75 | 2020 | |
| Abbvie INC. | $14.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edda Casanova listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.